Trending Stocks
AI-Detected Trends Before They Happen. Daily short-term research ideas with clear reasoning and a live model portfolio of trending stocks.
What “trending stocks” means here
On this page, trending stocks are the names the model is publishing now as short-term research ideas. They are not simply the market’s most-discussed tickers or the biggest one-day movers. Each idea has to pass the site’s selection process, is published with a clear entry date, and stays active for a seven-day holding window before moving into history.
The page separates current ideas, historical ideas, and portfolio-level performance so you can review what is active now, what has already closed, and how the published model record has developed over time.
Get daily or weekly stock research ideas.
Research content for general circulation. Not individualized advice.
Ideas Cumulative PerformanceCompounded
Fresh Ideas
Tue, Oct 13, 2026The newest batch from the model — 7 ideas published on Tue, Oct 13, 2026. Everything opened earlier in the week is in Active Ideas.
Shares gained 14% over 21 trading days through October 13 and finished 1.8% below their recent closing high. Strong profitability supports the momentum case, while heavy AI spending and resistance near $777.59 temper it.
Orders grew 7%, management raised fiscal 2026 adjusted EPS guidance to $6.55, and shares gained 10.4% over 21 trading days through October 13. A move above $162.46 would strengthen the near-term setup.
Shares gained about 16% over 21 trading days, including an October 8 breakout. An expanded CSL Plasma equipment-and-supplies agreement provides a concrete business catalyst, though its financial impact was not quantified.
Record Q2 revenue before reimbursable expenses grew 16% year over year. Shares gained about 13% over 21 trading days and closed at a period high after breaking above the recent $168 range.
Shares rose about 19.6% over 21 trading days amid strong VLCC freight conditions. A three-year charter at $100,000 per day begins in October, adding a specific near-term operating support; the rally also raises pullback risk.
Fiscal Q4 revenue and earnings beat expectations, supported by demand for large transformation projects. Shares gained about 10.3% over 21 trading days, although the recent rally makes entry timing important.
The October 2027 Medicare Advantage ratings update put 95% of members in plans rated at least four stars and helped drive an October 9 rally. Shares gained about 7.3% over 21 trading days, but the ratings benefit remains unquantified.
Closed Ideas
Tue, Oct 13, 2026Every idea that reached the end of its tracking window on the last completed trading day, with the result it actually finished on.
Second-quarter net income rose to $892 million from $208 million a year earlier amid favorable refining conditions. Shares gained about 6.4% over 21 sessions, though refining margins can reverse quickly.
On October 6, fiscal Q2 EPS of $1.17 beat the $0.59 estimate, revenue beat expectations, and management raised full-year sales and adjusted-EPS guidance. Shares jumped 19.5%; follow-through remains the key test.
Shares gained 7.8% over 21 sessions and broke above the prior high near $516. Management guided to roughly 45% first-quarter Azure growth in constant currency, citing demand above available capacity.
Q2 revenue rose 48%, demand for Mounjaro and Zepbound remains strong, and positive retatrutide Phase 3 results add pipeline support. Shares gained 3.4% over 21 sessions, though they have not broken above recent highs.
Third-quarter orders rose 56%, management raised its outlook, and Q4 revenue guidance implies 37% year-over-year growth at the midpoint. Shares finished October 6 at a 21-session high.
Shares gained 9.1% over 21 sessions, while fourth-quarter revenue guidance implies about 28% year-over-year growth at the midpoint. Program launches and aerospace, defense and industrial strength support the outlook.
Shares gained about 13% over 21 sessions and broke above their prior high. Reported 192% year-over-year E-Infrastructure growth and a record $4.33 billion backlog support near-term interest.
Shares gained 27.9% over 21 sessions. A record 1.6:1 book-to-bill ratio, sequential-growth guidance for fiscal Q4 led by Data Center, and positive quarterly free cash flow support the move.
Results are the model's tracked entry-to-exit move, before fees and slippage. See the full history.
Currently active model ideas with performance tracking
Shares gained 14% over 21 trading days through October 13 and finished 1.8% below their recent closing high. Strong profitability supports the momentum case, while heavy AI spending and resistance near $777.59 temper it.
Orders grew 7%, management raised fiscal 2026 adjusted EPS guidance to $6.55, and shares gained 10.4% over 21 trading days through October 13. A move above $162.46 would strengthen the near-term setup.
Shares gained about 16% over 21 trading days, including an October 8 breakout. An expanded CSL Plasma equipment-and-supplies agreement provides a concrete business catalyst, though its financial impact was not quantified.
Record Q2 revenue before reimbursable expenses grew 16% year over year. Shares gained about 13% over 21 trading days and closed at a period high after breaking above the recent $168 range.
Browse by Sector
Explore stock research ideas organized by industry sectors. Discover companies and investment opportunities across different market segments.
Best Recent Ideas
Top recent model ideas from our AI-powered pipeline with tracked outcomes
Jyong Biotech (MENS) has surged from $7.50 to over $23 post-IPO, showing exceptional short-term strength and clear higher highs/lows. Momentum traders targeting quick gains could capitalize on further follow-through, though underlying liquidity and trial risks remain significant.
USARW exhibits a strong short-term breakout with a 218% surge over 21 trading days well above its 21-day moving average and the upper Bollinger Band, signaling significant momentum. Despite elevated overbought risk, the strong technical strength and sector demand cyclicality make USARW a compelling hot idea for near-term trading gains with cautious risk management.
High-risk semiconductor test beneficiary with an imminent catalyst: multiple recent production orders (FOX wafer-level systems, silicon-photonics and GaN programs), reinstated H2 revenue guidance ($25–30M) and a sharp rebound (~+31% from March 30 to April 1) into the 2026-04-07 Q3 earnings release create a classic near-term event/momentum setup.
AeroVironment has outperformed its sector recently and sits on a technical base around $180–195 ahead of a June earnings release that could validate its strong profitability and revenue growth outlook. The BlueHalo merger adds a fresh growth narrative in drone defense, and the risk/reward looks favorable given the stock’s low leverage and positive analyst sentiment.
Model Ideas History
Complete track record of all published ideas with transparent outcomes.
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Oct 13, 2026 | Oct 20, 2026 | META | Meta Platforms, Inc. | Shares gained 14% over 21 trading days through October 13 and finished 1.8% below their recent closing high. Strong profitability supports the momentum case, while heavy AI spending and resistance near $777.59 temper it. | Active | +0.0% |
| Oct 13, 2026 | Oct 20, 2026 | EMR | Emerson Electric Co. | Orders grew 7%, management raised fiscal 2026 adjusted EPS guidance to $6.55, and shares gained 10.4% over 21 trading days through October 13. A move above $162.46 would strengthen the near-term setup. | Active | +0.0% |
| Oct 13, 2026 | Oct 20, 2026 | HAE | Haemonetics Corporation | Shares gained about 16% over 21 trading days, including an October 8 breakout. An expanded CSL Plasma equipment-and-supplies agreement provides a concrete business catalyst, though its financial impact was not quantified. | Active | +0.0% |
| Oct 13, 2026 | Oct 20, 2026 | HURN | Huron Consulting Group Inc. | Record Q2 revenue before reimbursable expenses grew 16% year over year. Shares gained about 13% over 21 trading days and closed at a period high after breaking above the recent $168 range. | Active | +0.0% |
| Oct 13, 2026 | Oct 20, 2026 | DHT | DHT Holdings, Inc. | Shares rose about 19.6% over 21 trading days amid strong VLCC freight conditions. A three-year charter at $100,000 per day begins in October, adding a specific near-term operating support; the rally also raises pullback risk. | Active | +0.0% |
| Oct 13, 2026 | Oct 20, 2026 | ACN | Accenture plc | Fiscal Q4 revenue and earnings beat expectations, supported by demand for large transformation projects. Shares gained about 10.3% over 21 trading days, although the recent rally makes entry timing important. | Active | +0.0% |
| Oct 13, 2026 | Oct 20, 2026 | HUM | Humana Inc. | The October 2027 Medicare Advantage ratings update put 95% of members in plans rated at least four stars and helped drive an October 9 rally. Shares gained about 7.3% over 21 trading days, but the ratings benefit remains unquantified. | Active | +0.0% |
| Oct 12, 2026 | Oct 19, 2026 | SEZL | Sezzle Inc. | Q2 revenue grew 51.7%, the full-year outlook was raised, and credit indicators improved. Shares closed October 12 just below their 21-session high after a roughly 19.7% rise since October 2; consumer-credit risk remains. | Active | -0.3% |
| Oct 12, 2026 | Oct 19, 2026 | APH | Amphenol Corporation | Record Q2 sales and adjusted EPS, 55% year-over-year sales growth, and strong IT datacom demand underpin a 9.8% share-price gain over 21 trading days. The stock remains below its October 6 peak. | Active | -0.4% |
| Oct 12, 2026 | Oct 19, 2026 | V | Visa Inc. | Visa reported 14% Q3 revenue growth and 11% EPS growth, with management expecting Q4 adjusted revenue growth at the high end of its low-double-digit range. Shares gained 4.2% over 21 trading days and closed above their period average. | Active | +1.7% |
How It Works
Our proprietary pipeline combines AI-powered analysis with systematic validation. Learn more about our methodology and check out our FAQ for details.
AI Analysis
Our pipeline continuously monitors news, earnings reports, technical indicators, and price action across thousands of stocks.
Multi-Layer Filtering
Ideas pass through multi-agent analysis framework: fundamental and news screening, technical confirmation, and risk assessment.
Publication & Alerts
Validated model ideas are published with clear reasoning. You may opt in to receive publication alerts.
How ideas are published and tracked
New ideas are published every business day. The system applies structured filters and a systematic research process, then posts the names that qualify for the current cycle. The homepage is built to separate what is live now from what has already finished:
- Active Ideas are the current seven-day ideas, with live performance while that window is open.
- Model Ideas History is the archive of closed ideas after their seven-day period ends.
- Ideas Cumulative Performance shows the compounded model-portfolio result across published ideas, using the site’s performance rules.
That distinction matters. A stock can be active today, then move into history once its window closes, while the cumulative chart keeps tracking the portfolio-level record across time rather than the result of any single name.
You can review current ideas in Active Ideas, browse past published ideas in Model Ideas History, and use Methodology & Disclosures for the calculation framework.
Frequently Asked Questions
Everything you need to know about Trending Stocks.
Important Legal Disclaimer
Not Investment Advice: All content on this platform is provided for informational and educational purposes only. Nothing on this site constitutes investment advice, financial advice, trading advice, or any other sort of advice.
No Guarantees: Past performance is not indicative of future results. All investments carry risk, and you may lose some or all of your capital.
Do Your Own Research: You are solely responsible for your own investment decisions. Always conduct thorough research and consider consulting with a qualified financial advisor.
Data Accuracy: While we strive for accuracy, we make no warranties about the completeness, reliability, or accuracy of information provided.
By using this service, you acknowledge that you have read and agree to our Terms of Service and Privacy Policy.